Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.

[1]  C. Miller,et al.  Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma , 2018, Clinical Cancer Research.

[2]  A. Nakao,et al.  Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model. , 2016, Journal of neurosurgery.

[3]  Y. Katayama,et al.  Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells , 2015, International journal of oncology.

[4]  W. Langridge,et al.  The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity , 2015, Vaccines.

[5]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[6]  Y. Katayama,et al.  Characterization of glioma stem-like cells from human glioblastomas , 2015, International journal of oncology.

[7]  A. Heimberger,et al.  Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege , 2014, Clinical Cancer Research.

[8]  Y. Cheng,et al.  Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors , 2014, Clinical Cancer Research.

[9]  H. Okano,et al.  Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. , 2013, Cancer research.

[10]  E. Satoh,et al.  Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. , 2013, Neurosurgery.

[11]  W. Wick,et al.  Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.

[12]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[13]  C. Piccirillo,et al.  Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.

[14]  Y. Katayama,et al.  Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas. , 2011, International journal of oncology.

[15]  E. Lander,et al.  Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells , 2011, Cell.

[16]  B. Katz,et al.  Haemophilus ducreyi Lipooligosaccharides Induce Expression of the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase via Type I Interferons and Tumor Necrosis Factor Alpha in Human Dendritic Cells , 2011, Infection and Immunity.

[17]  Seung-Up Kim,et al.  Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. , 2009, Cancer letters.

[18]  R. Weinberg,et al.  Cancer stem cells: mirage or reality? , 2009, Nature Medicine.

[19]  K. Moritake,et al.  Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation. , 2009, Journal of neurosurgery.

[20]  Y. Katayama,et al.  Effect of IFN-β on human glioma cell lines with temozolomide resistance , 2009 .

[21]  Yong Yang,et al.  Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. , 2009, Cancer letters.

[22]  C. Brosnan,et al.  Astrocyte Indoleamine 2,3-Dioxygenase Is Induced by the TLR3 Ligand Poly(I:C): Mechanism of Induction and Role in Antiviral Response , 2007, Journal of Virology.

[23]  Tai-Gyu Kim,et al.  Potentiation of antiglioma effect with combined temozolomide and interferon-beta. , 2006, Oncology reports.

[24]  M. Mizuno,et al.  Correction: IFN-β Down-Regulates the Expression of DNA Repair Gene MGMT and Sensitizes Resistant Glioma Cells to Temozolomide. , 2005, Cancer research.

[25]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[26]  M. Tada,et al.  Pluripotential competence of cells associated with Nanog activity , 2005, Mechanisms of Development.

[27]  B. Baban,et al.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.

[28]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[29]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[30]  M. Murakami,et al.  The Homeoprotein Nanog Is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells , 2003, Cell.

[31]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[32]  Milton W. Taylor,et al.  Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.